Fluticasone furoate /vilanterol (Breo Ellipta — GlaxoSmithKline) indication: chronic obstructive pulmonary disease
CADTH
Record ID 32015000174
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that fluticasone furoate/vilanterol (FF/V) be listed for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations, if clinical criteria are met.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_breo_ellipta_august_20_2014.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Drug Therapy, Combination
- Adrenergic beta-2 Receptor Agonists
- Androstadienes
- Benzyl Alcohols
- Bronchodilator Agents
- Chlorobenzenes
- Forced Expiratory Volume
- Glucocorticoids
- Pulmonary Disease, Chronic Obstructive
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.